Cargando…

Impact of HLA Class I Alleles on Timing of HIV Rebound After Antiretroviral Treatment Interruption

BACKGROUND: Identifying host determinants associated with HIV reservoir size and timing of viral rebound after an analytic treatment interruption (ATI) is an important step in the search for an HIV functional cure. We performed a pooled analysis of 103 participants from 4 AIDS Clinical Trials Group...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, You Jeong, Etemad, Behzad, Ahmed, Hayat, Naranbhai, Vivek, Aga, Evgenia, Bosch, Ronald J., Mellors, John W., Kuritzkes, Daniel R., Para, Michael, Gandhi, Rajesh T., Carrington, Mary, Li, Jonathan Z.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Pathogens and Immunity 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5761077/ https://www.ncbi.nlm.nih.gov/pubmed/29333522 http://dx.doi.org/10.20411/pai.v2i3.222

Ejemplares similares

Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV
por: Hill, Alison L., et al.
Publicado: (2016)

Correction: Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV
por: Hill, Alison L., et al.
Publicado: (2017)

Compartmentalized HIV rebound in the central nervous system after interruption of antiretroviral therapy
por: Gianella, Sara, et al.
Publicado: (2016)

Expression of type I interferon-associated genes at antiretroviral therapy interruption predicts HIV virological rebound
por: Zacharopoulou, P., et al.
Publicado: (2022)

Episomal Viral cDNAs Identify a Reservoir That Fuels Viral Rebound after Treatment Interruption and That Contributes to Treatment Failure
por: Sharkey, Mark, et al.
Publicado: (2011)

Correction: Real-Time Predictions of Reservoir Size and Rebound Time during Antiretroviral Therapy Interruption Trials for HIV
Publicado: (2016)

Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment
por: Aamer, Hadega A., et al.
Publicado: (2020)

Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection
por: Colby, Donn, et al.
Publicado: (2018)

Genetically-barcoded SIV facilitates enumeration of rebound variants and estimation of reactivation rates in nonhuman primates following interruption of suppressive antiretroviral therapy
por: Fennessey, Christine M., et al.
Publicado: (2017)

Phospholipid Metabolism Is Associated with Time to HIV Rebound upon Treatment Interruption
por: Giron, Leila B., et al.
Publicado: (2021)

TLR7 agonist, N6-LS and PGT121 delayed viral rebound in SHIV-infected macaques after antiretroviral therapy interruption
por: Hsu, Denise C., et al.
Publicado: (2021)

Impact of antiretroviral therapy in primary HIV infection on natural killer cell function and the association with viral rebound and HIV DNA following treatment interruption
por: Pace, Matthew, et al.
Publicado: (2022)

Host genetic variation and HIV disease: from mapping to mechanism
por: Naranbhai, Vivek, et al.
Publicado: (2017)

Immunological biomarkers predict HIV-1 viral rebound after treatment interruption
por: Hurst, Jacob, et al.
Publicado: (2015)

Models of SIV rebound after treatment interruption that involve multiple reactivation events
por: van Dorp, Christiaan H., et al.
Publicado: (2020)

Association of HLA-A and Non-Classical HLA Class I Alleles
por: Carlini, Federico, et al.
Publicado: (2016)

HLA class I allele promiscuity revisited
por: Rao, Xiangyu, et al.
Publicado: (2011)

To rebound or not to rebound
por: Stahl, Bethany A, et al.
Publicado: (2017)

Increased Proviral DNA in Circulating Cells Correlates with Plasma Viral Rebound in Simian Immunodeficiency Virus-Infected Rhesus Macaques after Antiretroviral Therapy Interruption
por: Ziani, Widade, et al.
Publicado: (2021)

A closer look at rituximab induction on HLA antibody rebound following HLA incompatible kidney transplantation
por: Jackson, Annette M., et al.
Publicado: (2014)

Distribution of HLA class I alleles and haplotypes in Korean.
por: Kim, T. G., et al.
Publicado: (1993)

HLA class I alleles frequencies in the Syrian population
por: Ikhtiar, Adnan M., et al.
Publicado: (2018)

HLA Heterozygote Advantage against HIV-1 Is Driven by Quantitative and Qualitative Differences in HLA Allele-Specific Peptide Presentation
por: Arora, Jatin, et al.
Publicado: (2020)

Transcriptional Changes in CD8(+) T Cells During Antiretroviral Therapy Intensified With Raltegravir
por: Ouyang, Zhengyu, et al.
Publicado: (2015)

Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles
por: Pavlos, Rebecca, et al.
Publicado: (2017)

Increased Risk of Virologic Rebound in Patients on Antiviral Therapy with a Detectable HIV Load <48 Copies/mL
por: Henrich, Timothy J., et al.
Publicado: (2012)

The risk of viral rebound in the year after delivery in women remaining on antiretroviral therapy
por: Huntington, Susie, et al.
Publicado: (2015)

Dynamics and origin of rebound viremia in SHIV-infected infant macaques following interruption of long-term ART
por: Obregon-Perko, Veronica, et al.
Publicado: (2021)

HLA alleles associated with COVID-19 susceptibility and severity in different populations: a systematic review
por: Fakhkhari, Meryem, et al.
Publicado: (2023)

Association of HLA alleles with autism
por: Sayad, Arezou, et al.
Publicado: (2018)

108. Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy
por: Gandhi, Rajesh, et al.
Publicado: (2020)

Continuing or adding IL-2 in patients treated with antiretroviral therapy (ACTG Protocol A5051, a rollover trial of ACTG Protocol A328)
por: Bosch, Ronald J, et al.
Publicado: (2010)

The novel HLA class I allele, HLA‐B*14:110, identified by next‐generation sequencing
por: Laustsen, Mira Marie, et al.
Publicado: (2022)

HLA-B(*)57 Allele Is Associated with Concomitant Anti-tuberculosis and Antiretroviral Drugs Induced Liver Toxicity in Ethiopians
por: Petros, Zelalem, et al.
Publicado: (2017)

Novel HLA Class I Alleles Associated with Indian Leprosy Patients
por: Shankarkumar, U., et al.
Publicado: (2003)

Prediction of HLA Class II Alleles Using SNPs in an African Population
por: Ayele, Fasil Tekola, et al.
Publicado: (2012)

Cytomegalovirus Infection in Ireland: Seroprevalence, HLA Class I Alleles, and Implications
por: Hassan, Jaythoon, et al.
Publicado: (2016)

The ethical case for placebo control in HIV-cure-related studies with ART interruption
por: Magalhaes, Monica, et al.
Publicado: (2022)

PyHLA: tests for the association between HLA alleles and diseases
por: Fan, Yanhui, et al.
Publicado: (2017)

Associations of Moyamoya patients with HLA class I and class II alleles in the Korean population.
por: Han, Hoon, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_ba2lkavcflhg4ke9h450qml06q